癌症中IL-6信号通路研究进展  

Interleukin- 6 signaling pathway in cancer

作　　者：唐甜[1] 安东建[2] 曹建国[3] 

机构地区：[1]南华大学,湖南衡阳421001 [2]长沙市中心医院肿瘤研究所,湖南长沙410004 [3]湖南师范大学医学院药物工程实验室,湖南长沙410013

出　　处：《现代肿瘤医学》2016年第9期1470-1472,共3页Journal of Modern Oncology

基　　金：国家自然科学基金(编号:81172375);湖南省自然科学基金(编号:03jjy5009)

摘　　要：IL-6是一种多效细胞因子。IL-6在肿瘤患者外周血和肿瘤组织中均呈现高表达。IL-6与其相应受体结合,受体复合物结合gp130后活化STAT3和Twist,导致E-cadherin表达下调,N-cadherin、Vimentin、Snail等蛋白表达上调,诱发癌细胞发生上皮-间充质转化,从而增强癌细胞的侵袭力和远处转移能力。因此,对IL-6/STAT3/Twist信号通路的深入研究,可能为揭示癌症的发病机制研究开辟新的方向,为研发针对此信号通路来治疗癌症的特异性药物提供了理论基础。本文针对近期的研究进展作一综述。IL- 6 is an inflammatory cytokine with various effects. IL- 6 level is increased in peripheral blood and tumor tissue in patients with tumor. IL -6 combines its corresponding receptors, gpl30, then activates STAT3 and Twist, and down- regulates E- cadherin expression, and upregulates N- cadherin, Vimentin and Snail protein expression, inducing epithelial- ectomesenchymal transformation（EMT） in cancer cells, which accordingly enhances invasiveness and distant metastasis of cancer cells. Therefore, the study in terms of IL -6/STAT3/Twist signaling pathways may reveal the pathogenesis of cancer, which open up a new aspect to provide a theoretical basis for the specifici- ty of the drug developement for treating cancer. This paper reviewed the recent progress in the field.

关 键 词：IL-6 STAT3 TWIST 癌症 研究进展 

分 类 号：R730.231[医药卫生—肿瘤]